Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
Disclosure of Conflicts of Interest
Boston University Disclosure
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Clinical Care Options Disclosure
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Cara D. Dolin, MD, MPH, has no relevant financial relationships to disclose.
Diana Girnita, MD, PhD: no relevant financial relationships to disclose.
Jennifer L. Simpson, DNP, has no relevant financial relationships to disclose.Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product. The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education have no relevant financial relationships with ineligible companies: Michael Burk, BS – Senior Program Manager, Ilana Hardesty, MA – Assistant Director, Operations.
Dr. Monica Crespo-Bosque, Boston University Chobanian & Avedisian School of Medicine’s activity Course Director conducts clinical trials for Biogen.
Dr. Michael York, Boston University Chobanian & Avedisian School of Medicine’s independent auditor, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Target Audience
The intended audience for this national educational initiative is rheumatologists, OB/GYNs, and other healthcare professionals within the US who prescribe and/or participate in the treatment of patients taking mycophenolate products, including physicians, nurse practitioners, and physician associates who write prescriptions for mycophenolate products and pharmacists who dispense these products and assist in the care of patients taking mycophenolate products.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the pregnancy and fetal risks associated with mycophenolate use in female patients of reproductive potential
- Educate and counsel female patients of reproductive potential on the need for pregnancy prevention and planning during mycophenolate treatment
- Select safe mycophenolate alternatives for female patients who are pregnant or considering pregnancy
- Promptly report pregnancies that occur during mycophenolate treatment to the Mycophenolate Pregnancy Registry
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Clinical Care Options, LLC. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Boston University Chobanian & Avedisian School of Medicine designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nursing Continuing Professional Development
Contact Hours: 1, all of which is eligible for pharmacology credit.Continuing Pharmacy Education
This activity is approved for 1 CPE credit(s) under the ACPE universal activity number JA0000185-9999-23-013-H01-P. The activity is available for credit claiming through 60 days after completing this enduring activity.
Physician Associate/Physician Assistant Continuing Medical Education
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until November 29, 2024. PAs should only claim credit commensurate with the extent of their participation.Provider(s)/Educational Partner(s)
Provided by Boston University Chobanian & Avedisian School of Medicine, in partnership with Clinical Care Options, LLC
Commercial Support
This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food
Disclaimer
Boston University Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.Clinical Care Options Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Lawrence Eichenfield, MD, FAAD
Martina J. Porter, MD
Joel M. Gelfand, MD, MSCE
Lloyd Miller, MD, PhD
Martin Metz, MD
Jay Reddy, MD, FASN
Carlos Narváez Mejía, MD
Kieran McCafferty, MD
Prof. Dr. Jörg Latus
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD